
|Articles|July 1, 2017
Adverse Reactions Associated with Biologics for Moderate-to-Severe Plaque Psoriasis
In July, our table of the month sums up biologics approved for moderate-to-severe plaque psoriasis and common adverse events associated with these biologics.
Advertisement
Links to PDF
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
The Intersection of Acne, Atopic Dermatitis, and Modern Skin Care
3
Brepocitinib Demonstrates Superior Efficacy in Phase 2 BEACON Trial for Cutaneous Sarcoidosis
4
Depth, Speed, and Durability: What Matters Most in Modern Clinical Trials
5











